ArticleEJNMMI research2020
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients.
Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Dual-time-point [EJNMMI research · 2026Article
- Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.Current treatment options in oncology · 2025Review
- Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study.Cancers · 2025Article
- Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors.Targeted oncology · 2024Review
- Clinical application ofJapanese journal of radiology · 2024Review
- An overview on multimodal imaging for the diagnostic workup of pleural mesothelioma.Japanese journal of radiology · 2024Review
- PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B-cell lymphoma patients.Frontiers in oncology · 2024Article
- Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma.Frontiers in oncology · 2024Article
- Methodological evaluation of original articles on radiomics and machine learning for outcome prediction based on positron emission tomography (PET).Nuklearmedizin. Nuclear medicine · 2023Review
- Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer.NPJ precision oncology · 2023Review
- Predicting survival for patients with mesothelioma: development of the PLACE prognostic model.BMC cancer · 2023Article
- New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Predicting cancer outcomes with radiomics and artificial intelligence in radiology.Nature reviews. Clinical oncology · 2022Review
- The Prognostic Value ofJournal of clinical medicine · 2021Review
- Radiomics in surgical oncology: applications and challenges.Computer assisted surgery (Abingdon, England) · 2021Review
- New Updates of the Imaging Role in Diagnosis, Staging, and Response Treatment of Malignant Pleural Mesothelioma.Cancers · 2021Review
- Multiblock Discriminant Analysis of IntegrativeInternational journal of radiation oncology, biology, physics · 2021Article
- Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis.Oncotarget · 2021Article
- The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.Journal of clinical medicine · 2021Review
- A Systematic Review of PET Textural Analysis and Radiomics in Cancer.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundCareful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of substantial toxicity. Radiomics-a quantitative method for image analysis-has shown its prognostic ability in different tumor entities and could therefore play an important role in optimizing patient selection for radical cancer treatment. So far, radiomics as a prognostic tool in MPM was not investigated. MATERIALS AND
methodsThis study is based on 72 MPM patients treated with surgery in a curative intent at our institution between 2009 and 2017. Pre-treatment Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for radiomics outcome modeling. After extraction of 1404 CT and 1410 FDG PET features from each image, a preselection by principal component analysis was performed to include only robust, non-redundant features for the cox regression to predict the progression-free survival (PFS) and the overall survival (OS). Results were validated on a separate cohort. Additionally, SUVmax and SUVmean, and volume were tested for their prognostic ability for PFS and OS.
resultsFor the PFS a concordance index (c-index) of 0.67 (95% CI 0.52-0.82) and 0.66 (95% CI 0.57-0.78) for the training cohort (n = 36) and internal validation cohort (n = 36), respectively, were obtained for the PET radiomics model. The PFS advantage of the low-risk group translated also into an OS advantage. On CT images, no radiomics model could be trained. SUV max and SUV mean were also not prognostic in terms of PFS and OS.
conclusionWe were able to build a successful FDG PET radiomics model for the prediction of PFS in MPM. Radiomics could serve as a tool to aid clinical decision support systems for treatment of MPM in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.